Standard Lipid Panel: Which Tests to Order Alongside for Complete Cardiovascular Risk Assessment

What a Standard Lipid Panel Actually Measures

A standard lipid panel reports four values: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Non-HDL cholesterol is then calculated as TC minus HDL-C. These five numbers form the backbone of cardiovascular risk assessment in primary and specialty care, and the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol treats LDL-C as the primary target for therapy.

Total Cholesterol

Total cholesterol is the sum of LDL-C, HDL-C, and very-low-density lipoprotein cholesterol (VLDL-C). A value <200 mg/dL is considered desirable. The number alone, though, is a blunt instrument. A person with a TC of 220 mg/dL driven by high HDL-C carries far less risk than one with the same TC driven by high LDL-C. Context always matters.

LDL-C: The Primary Treatment Target

LDL-C is estimated via the Friedewald equation in most clinical labs: LDL-C = TC - HDL-C - (TG/5). That formula breaks down when triglycerides exceed 400 mg/dL, which is when direct LDL-C measurement is required. The 2018 ACC/AHA guideline defines optimal LDL-C as <70 mg/dL for very-high-risk patients and <100 mg/dL for high-risk patients [1].

HDL-C and Triglycerides

HDL-C >60 mg/dL is considered protective. HDL-C <40 mg/dL in men and <50 mg/dL in women is a recognized risk enhancer. Triglycerides <150 mg/dL are normal; values ≥200 mg/dL suggest metabolic dysfunction, and values ≥500 mg/dL carry independent pancreatitis risk. The American Heart Association's 2011 triglyceride statement classifies 150-199 mg/dL as borderline high and 200-499 mg/dL as high [2].

Normal Ranges for Each Component

Reference intervals vary slightly by laboratory, but the values below reflect the consensus from ACC/AHA and National Lipid Association guidelines.

| Component | Desirable | Borderline | High Risk | |---|---|---|---| | Total Cholesterol | <200 mg/dL | 200-239 mg/dL | ≥240 mg/dL | | LDL-C | <100 mg/dL | 130-159 mg/dL | ≥160 mg/dL | | HDL-C | >60 mg/dL | 40-59 mg/dL (men) | <40 mg/dL (men) | | Triglycerides | <150 mg/dL | 150-199 mg/dL | ≥200 mg/dL | | Non-HDL-C | <130 mg/dL | 160-189 mg/dL | ≥190 mg/dL |

The USPSTF recommends lipid screening for adults 21 and older who have increased cardiovascular risk [3]. For children with a family history of familial hypercholesterolemia, the American Academy of Pediatrics endorses universal screening between ages 9 and 11.

Why Non-HDL-C Deserves Attention

Non-HDL-C captures cholesterol carried in all atherogenic particles, not just LDL. It is a better predictor of cardiovascular events than LDL-C alone in patients with high triglycerides or metabolic syndrome. The target for non-HDL-C is typically 30 mg/dL higher than the corresponding LDL-C target, so a very-high-risk patient aiming for LDL-C <70 mg/dL should target non-HDL-C <100 mg/dL [1].

What High or Low Results Mean Clinically

High LDL-C

LDL-C ≥190 mg/dL in an adult almost always warrants investigation for familial hypercholesterolemia (FH). The CASCADE FH Registry demonstrated that fewer than 10% of FH patients in the United States had been diagnosed before a cardiovascular event [4]. High-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg) is the first-line intervention per ACC/AHA guidelines, targeting at least a 50% LDL-C reduction.

When LDL-C is elevated in the 130-189 mg/dL range, clinicians use the Pooled Cohort Equations (PCE) to calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk before initiating pharmacotherapy. A 10-year ASCVD risk ≥7.5% generally justifies statin therapy.

Low HDL-C

Low HDL-C is a risk enhancer, not an independent therapeutic target. The AIM-HIGH trial (N=3,414) showed that niacin added to statin therapy raised HDL-C by a mean of 25% but did not reduce cardiovascular events compared to statin alone [5]. Aerobic exercise, smoking cessation, and weight loss remain the most evidence-backed interventions for raising HDL-C.

High Triglycerides

Elevated triglycerides above 500 mg/dL require prompt treatment to prevent pancreatitis. Fibrates (fenofibrate 145 mg daily or gemfibrozil 600 mg twice daily) and prescription omega-3 fatty acids (icosapentaenoic acid 4 g/day, i.e., icosapent ethyl/Vascepa) are first-line agents. The REDUCE-IT trial (N=8,179) showed icosapent ethyl 4 g/day reduced major adverse cardiovascular events by 25% in patients with elevated triglycerides (150-499 mg/dL) already on statins (HR 0.75, 95% CI 0.68-0.83, P<0.001) [6].

Low LDL-C

Very low LDL-C (<40 mg/dL) may occur with PCSK9 inhibitor therapy or rare genetic conditions. ODYSSEY OUTCOMES and FOURIER trial data show that LDL-C values as low as 15-20 mg/dL with alirocumab or evolocumab are safe and associated with further cardiovascular risk reduction, without increased rates of hemorrhagic stroke or neurocognitive events [7].

Which Tests to Order Alongside a Standard Lipid Panel

This section is the clinical core of the article. A standard lipid panel alone leaves several major cardiovascular risk drivers unmeasured. The tests below, ordered strategically, close those gaps.

Apolipoprotein B (ApoB)

ApoB is the structural protein on every atherogenic lipoprotein particle, including LDL, VLDL, IDL, and Lp(a). Each particle carries exactly one ApoB molecule, so ApoB concentration equals total atherogenic particle count. This matters because LDL-C and particle count can diverge significantly in patients with metabolic syndrome, insulin resistance, or hypertriglyceridemia.

The American Diabetes Association Standards of Care 2024 recommends ApoB measurement in patients with diabetes when LDL-C may be falsely reassuring [8]. The AACE/ACE Comprehensive Diabetes Management Algorithm also identifies ApoB as a preferred secondary target in high-risk patients. An ApoB goal of <80 mg/dL corresponds roughly to an LDL-C goal of <70 mg/dL.

Order ApoB alongside the standard lipid panel whenever:

• Triglycerides are ≥200 mg/dL (Friedewald equation unreliable)
• The patient has type 2 diabetes or metabolic syndrome
• LDL-C appears well-controlled but non-HDL-C or residual risk remains a concern
• Monitoring PCSK9 inhibitor therapy response

Lipoprotein(a) (Lp(a))

Lp(a) is a genetically determined atherogenic particle that is not modified by diet or most standard lipid-lowering drugs. The European Atherosclerosis Society 2022 Lp(a) consensus statement recommends measuring Lp(a) at least once in every adult to identify those with high inherited risk [9]. Elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L) is present in approximately 20% of the global population and confers a cardiovascular risk equivalent to heterozygous familial hypercholesterolemia.

Lp(a) does not require fasting. It is stable, changes <10% with diet, and needs to be measured only once in most patients unless a major cardiovascular event or a new family history finding emerges.

Current options for lowering Lp(a) are limited. PCSK9 inhibitors reduce Lp(a) by 20-30%. Pelacarsen, an RNA-targeted therapy in phase 3 trials (Lp(a)HORIZON, NCT04023552), reduced Lp(a) by 80% in phase 2 data [10].

High-Sensitivity C-Reactive Protein (hsCRP)

HsCRP is a marker of systemic inflammation that adds risk information independent of the lipid panel. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with LDL-C <130 mg/dL but hsCRP ≥2.0 mg/L, establishing hsCRP as a threshold for statin initiation in otherwise borderline-risk patients [11].

The 2018 ACC/AHA guideline lists hsCRP ≥2.0 mg/L as a risk-enhancing factor that may tip the decision toward statin therapy in intermediate-risk patients (10-year ASCVD 7.5-19.9%). A single hsCRP measurement on a non-acutely ill patient is sufficient for risk stratification.

Fasting Glucose and HbA1c

Diabetes and prediabetes are potent cardiovascular risk multipliers. The ACC/AHA guideline treats diabetes as a condition that automatically places patients in the high-risk category. Ordering fasting glucose and HbA1c with every lipid panel ensures that undiagnosed diabetes (affecting an estimated 8.5 million Americans per CDC data [12]) does not go unrecognized alongside borderline lipid values.

HbA1c ≥6.5% confirms diabetes. HbA1c 5.7-6.4% indicates prediabetes and warrants lifestyle intervention and repeat testing in 1-3 years per ADA 2024 guidelines.

Thyroid-Stimulating Hormone (TSH)

Hypothyroidism elevates LDL-C, total cholesterol, and triglycerides through reduced LDL receptor expression and slowed lipoprotein clearance. Initiating statin therapy without ruling out hypothyroidism risks treating a secondary dyslipidemia rather than a primary one. TSH >4.5 mIU/L warrants levothyroxine replacement before or concurrent with lipid-lowering therapy, as treated hypothyroidism can normalize lipid values without pharmacotherapy.

Order TSH with any new lipid panel showing unexplained LDL-C ≥160 mg/dL or total cholesterol ≥240 mg/dL, particularly in women over 50.

Fasting Insulin and HOMA-IR

Standard lipid panels do not measure insulin resistance directly. A fasting insulin level combined with fasting glucose allows calculation of HOMA-IR (fasting insulin x fasting glucose / 405). A HOMA-IR >2.5 suggests clinically meaningful insulin resistance, which drives the atherogenic dyslipidemia pattern of high triglycerides, low HDL-C, and a preponderance of small dense LDL particles.

Identifying insulin resistance early changes the therapeutic approach. GLP-1 receptor agonists (semaglutide, liraglutide) and weight management become primary interventions alongside statins in this population.

Comprehensive Metabolic Panel (CMP)

A CMP checks liver enzymes (AST, ALT), creatinine, and eGFR. These are relevant to lipid management for two reasons. First, statins require baseline liver enzyme measurement; a finding of ALT >3x the upper limit of normal is a relative contraindication. Second, chronic kidney disease (eGFR <60 mL/min/1.73 m2) itself confers elevated cardiovascular risk and may alter statin dosing, with the 2013 KDIGO guidelines recommending statin use in most CKD patients not on dialysis.

A Practical Paired-Test Framework by Clinical Scenario

| Clinical Scenario | Add to Standard Lipid Panel | |---|---| | Routine adult screening, no known risk factors | hsCRP, fasting glucose, TSH | | Type 2 diabetes or prediabetes | ApoB, HbA1c, fasting insulin, CMP | | Suspected familial hypercholesterolemia (LDL ≥190) | Lp(a), ApoB, genetic testing referral | | Metabolic syndrome or obesity (BMI ≥30) | ApoB, fasting insulin, HOMA-IR, HbA1c | | High triglycerides (≥200 mg/dL) | ApoB (direct LDL), fasting glucose, TSH | | Intermediate ASCVD risk (10-year 7.5-19.9%) | hsCRP, Lp(a), coronary artery calcium score | | Monitoring statin or PCSK9 inhibitor therapy | ApoB, CMP (LFTs), CK if myalgia reported |

How to Lower Lipid Panel Values

Therapeutic interventions target specific lipid fractions rather than the panel as a whole.

Lowering LDL-C

High-intensity statin therapy is the first line. Atorvastatin 40-80 mg reduces LDL-C by 50-60%; rosuvastatin 20-40 mg achieves similar reductions. For patients who cannot tolerate daily statins, alternate-day rosuvastatin or ezetimibe (10 mg/day, reducing LDL-C by an additional 13-20% on top of statins) are validated options. PCSK9 inhibitors (alirocumab 75-150 mg every 2 weeks or evolocumab 140 mg every 2 weeks) reduce LDL-C by 50-60% on top of maximally tolerated statin therapy [7].

Dietary changes provide modest but real LDL-C reductions. Replacing saturated fat with polyunsaturated fat lowers LDL-C by approximately 5-10 mg/dL for every 1% of calories substituted, per AHA dietary guidance [13].

Lowering Triglycerides

Reducing refined carbohydrate and alcohol intake is the most effective lifestyle intervention for hypertriglyceridemia. Prescription omega-3 fatty acids (icosapent ethyl 4 g/day) and fibrates are the pharmacological standards. Weight loss of 5-10% body weight reduces triglycerides by 20% on average.

Raising HDL-C

Aerobic exercise (150 minutes per week of moderate-intensity activity) raises HDL-C by 3-9 mg/dL in most studies. Smoking cessation adds 4 mg/dL on average. No pharmacological agent has demonstrated clinical benefit specifically from HDL-C raising, as the AIM-HIGH and HPS2-THRIVE trials both failed to show benefit from niacin or cholesteryl ester transfer protein inhibition despite significant HDL-C increases [5].

Fasting Requirements and Pre-Test Considerations

Triglycerides and calculated LDL-C (Friedewald equation) are accurate only in the fasted state. A 9-12-hour fast is standard. Total cholesterol and HDL-C change by less than 2% with food intake, so non-fasting panels are acceptable when triglycerides and LDL-C are not the primary clinical question.

The American Heart Association and American College of Cardiology note that non-fasting samples are acceptable for initial cardiovascular risk screening when fasting is inconvenient, with a follow-up fasting panel if triglycerides are ≥200 mg/dL [1]. Acute illness, corticosteroid use, and pregnancy all alter lipid values and should prompt repeat testing once the acute condition resolves.

Screening Frequency and Monitoring Intervals

The USPSTF recommends lipid screening for all men 35 and older and for younger adults with cardiovascular risk factors [3]. For patients on statin therapy, repeat the lipid panel 4-12 weeks after initiating or changing therapy, then every 3-12 months thereafter, per ACC/AHA guidance.

Patients on PCSK9 inhibitors should have a fasting lipid panel and ApoB drawn 4-8 weeks after each dose change. ApoB is the preferred monitoring marker when baseline triglycerides are elevated because it reflects particle count rather than calculated cholesterol content.

As the 2018 ACC/AHA Blood Cholesterol Guideline states: "The intensity of LDL-C lowering should be sufficient to achieve at least a 50% reduction from baseline in very high-risk patients, with an LDL-C goal of less than 70 mg/dL" [1]. Tracking ApoB alongside LDL-C ensures that particle burden is addressed even when calculated LDL-C appears to have reached target.